CFO Mark Andersen resigns; Board member Robert Hoffman appointed Interim CFO

FibroBiologics, Inc.

Mark Andersen resigns as CFO effective up to Nov 15, 2024; will transition duties.
Robert Hoffman, current Board member, appointed Interim CFO effective Oct 30, 2024.
Hoffman receives $45,833/month cash compensation; steps down from Audit/Compensation Committees.
Richard Cilento becomes Audit Committee Chairman; Stacy Coen joins Audit; Matthew Link leads Compensation Committee.
Andersen eligible for nine months base salary severance plus COBRA reimbursement on signing release.

item 5.02 item 8.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Mark Andersen

Chief Financial Officer

FBLG · FibroBiologics, Inc.

Filed: October 29, 2024, 7:59 PM ET

On October 25, 2024, Mr. Mark Andersen informed FibroBiologics, Inc. (the “Company”) of his decision to voluntarily resign from his position as the Company’s Chief Financial Officer

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mark Andersen resigned as Chief Financial Officer at FibroBiologics, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

On October 25, 2024, Mr. Mark Andersen informed FibroBiologics, Inc. (the “Company”) of his decision to voluntarily resign from his position as the Company’s Chief Financial Officer

View on SEC.gov

FibroBiologics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-042867

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.